Supplementary Figure 2.

A. List of top candidate compounds from immunofluorescence screen with their respective fold changes for insulin and glucagon expression, and for the number of DAPI-positive nuclei, as measured via immunofluorescence intensity. B. Loperamide dose ressponse suppression of glucagon transcription in Min6 cells treated with FoxO inhibitor. C. Glucagon mRNA levels in Min6 cells following loperamide time course, as measured by RT-qPCR. D. PPAR-gamma and Aldh1a3 transcription in Min6 cells treated with FoxOi/loperamide for 48h, measured by RNAseq. E. Gene ontology enrichment terms for RNAseq dataset of genes significantly downregulated by FoxOi and significantly rescued by loperamide after 48h treatment in Min6 cells.